• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

6,165
2,283
1,853
1,828
1,712

COUNTRY

871
643
263
249
208

CATEGORIES

  • 856
  • 184
  • 950
  • 1,126
    • 99
  • 385
  • 270
  • 252
  • 65
  • 379
  • 673
  • 1,257
  • 1,621
  • 625
  • 883
  • 1,674
  • 2,640
    • 574
    • 118
    • 550
    • 75
    • 526
    • 43
    • 505
    • 18
    • 18
    • 23
  • 505
  • 726
  • 0
  • 97

PRICE

6,960
11,315
17,028
24,680

PUBLISHED

243
2,338
6,775
24,680

PRODUCT TYPE

20,305
3,174
856
164
74
44
21
21
14
6
1

Pharmaceuticals

The pharmaceutical industry has been for decades one of the most profitable worldwide. Serious challenges, such as the expiry of long-term lucrative patents (Lipitor, to mention just one) and the cuts in healthcare and R&D in many countries worldwide, can pose a challenge to the growth of the industry. Which drug can save the life of the pharmaceutical industry? Highly differentiated strategies: this is what companies should focus on now if they want to stay competitive. Do you want to know more?

You can get a detailed picture of the market and refine your marketing, brand, and sales strategies with the reliable, up-to-date business information provided by the extensive range of reports, books and subscriptions listed under Research and Markets’ Pharmaceuticals category. They cover markets, companies (big Pharma, mid-sized specialty pharmaceutical companies, generic manufacturers, and small firms), technologies, e-healthcare, pharmaeconomics, drug discovery, and drug delivery.

The product coverage is huge. It includes OTC drugs as well disorder and goal-specific products related to respiration, oncology, vitamins, cardio, analgesics, central nervous system, generics, immune disorders, and women’s health. Show Less
Read more

PRODUCT TITLE

Chemotherapy Effects - Pipeline Review, H2 2013

Chemotherapy Effects - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Chemotherapy Effects - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This...

July 2013
FROM

Chronic Heart Failure - Pipeline Review, H2 2013

Chronic Heart Failure - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Chronic Heart Failure - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

July 2013
FROM

Substance (Drug) Abuse - Pipeline Review, H2 2013

Substance (Drug) Abuse - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Substance (Drug) Abuse - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

July 2013
FROM

Autoimmune Disorders - Pipeline Review, H2 2013

Autoimmune Disorders - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Autoimmune Disorders - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This...

July 2013
FROM

Hodgkin Lymphoma - Pipeline Review, H2 2013

Hodgkin Lymphoma - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Hodgkin Lymphoma - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report...

July 2013
FROM

Peritoneal Cancer - Pipeline Review, H2 2013

Peritoneal Cancer - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Peritoneal Cancer - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report...

July 2013
FROM

Lymphangioleiomyomatosis - Pipeline Review, H2 2013

Lymphangioleiomyomatosis - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Lymphangioleiomyomatosis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

July 2013
FROM

Vulvovaginal Candidiasis - Pipeline Review, H2 2013

Vulvovaginal Candidiasis - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Vulvovaginal Candidiasis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

July 2013
FROM

Refractory Multiple Myeloma - Pipeline Review, H2 2013

'Refractory Multiple Myeloma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline This report provides information on the therapeutic development for Refractory...

July 2013
FROM

Chronic Bronchitis - Pipeline Review, H2 2013

Chronic Bronchitis - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Chronic Bronchitis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This...

July 2013
FROM

Malignant Pleural Mesothelioma - Pipeline Review, H2 2013

Malignant Pleural Mesothelioma - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Malignant Pleural Mesothelioma - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic...

July 2013
FROM

Diabetic Gastroparesis - Pipeline Review, H2 2013

Diabetic Gastroparesis - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Diabetic Gastroparesis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

July 2013
FROM

Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H2 2013

Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H2 2013', provides...

July 2013
FROM

Ischemia - Pipeline Review, H2 2013

Ischemia - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Ischemia - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

July 2013
FROM

Fungal Infections - Pipeline Review, H2 2013

Fungal Infections - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Fungal Infections - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report...

July 2013
FROM

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2013

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Metastatic Hormone Refractory (Castration Resistant,...

July 2013
FROM

Injury - Pipeline Review, H2 2013

'Injury - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline This report provides information on the therapeutic development for Injury, complete with latest updates,...

July 2013
FROM

Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2013

Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic...

July 2013
FROM

Medullary Thyroid Cancer - Pipeline Review, H2 2013

Medullary Thyroid Cancer - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Medullary Thyroid Cancer - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

July 2013
FROM

Myocardial Ischemia - Pipeline Review, H2 2013

Myocardial Ischemia - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Myocardial Ischemia - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This...

July 2013
FROM
Loading Indicator

Our Clients

Our clients' logos